Alkermes plc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)
Alkermes plc. (ALKS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) of -$1.27 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss · last filed 2022-11-02
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-09-30 was -$230.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-06-30 was -$542.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-03-31 was -$501.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2021-12-31 was -$29.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2021 was -$7.94M.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2020 was -$3.89M.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2014 was -$383.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2013 was -$12.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$772.00K derived: sum of 2 quarters · filed 2022-11-02 | -$1.27M 10-Q · filed 2022-11-02 | -$1.30M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | -$542.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$1.04M 10-Q · filed 2022-07-27 | -$1.07M derived: sum of 3 quarters · filed 2022-07-27 | -$1.09M derived: sum of 4 quarters · filed 2022-07-27 |
| 2022-03-31 | -$501.00K 10-Q · filed 2022-04-27 | -$530.00K derived: sum of 2 quarters · filed 2022-04-27 | -$549.00K derived: sum of 3 quarters · filed 2022-04-27 | -$2.01M derived: sum of 4 quarters · filed 2022-04-27 |
| 2021-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$48.00K derived: sum of 2 quarters · filed 2022-02-16 | -$1.51M derived: sum of 3 quarters · filed 2022-02-16 | -$7.94M 10-K · filed 2022-02-16 |
| 2021-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | -$1.48M derived: sum of 2 quarters · filed 2021-10-27 | -$7.91M 10-Q · filed 2021-10-27 | -$8.97M derived: sum of 4 quarters · filed 2021-10-27 |
| 2021-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$7.89M 10-Q · filed 2021-07-28 | -$8.96M derived: sum of 3 quarters · filed 2021-07-28 | |
| 2021-03-31 | -$6.43M 10-Q · filed 2021-04-28 | -$7.50M derived: sum of 2 quarters · filed 2021-04-28 | ||
| 2020-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$3.89M 10-K · filed 2021-02-11 | ||
| 2020-09-30 | -$2.82M 10-Q · filed 2020-10-29 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $0.00 derived: sum of 2 quarters · filed 2015-02-24 | -$167.00K derived: sum of 3 quarters · filed 2015-02-24 | -$383.00K 10-K · filed 2015-02-24 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$167.00K derived: sum of 2 quarters · filed 2014-10-29 | -$383.00K 10-Q · filed 2014-10-29 | |
| 2014-06-30 | -$167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$383.00K 10-Q · filed 2014-07-31 | ||
| 2014-03-31 | -$216.00K 10-Q · filed 2014-04-30 | |||
| 2013-12-31 | $719.00K 10-KT · filed 2014-02-27 | |||
| 2013-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $0.00 derived: sum of 2 quarters · filed 2013-05-23 | -$12.00K 10-K · filed 2013-05-23 | |
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | -$12.00K 10-Q · filed 2013-01-31 | ||
| 2012-09-30 | -$12.00K 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |